Forte Biosciences Inc
FBRX27.590USD
-1.220-4.23%
終値 02/06, 16:00（ET）15分遅れの株価
345.53M時価総額
損失額直近12ヶ月PER
詳細情報 Forte Biosciences Inc 企業名
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is an anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. It is advancing clinical development of FB102 into patient-based trials for celiac disease and non-segmental vitiligo. The Company's FB102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and certain T cell subsets. FB102 has potentially other autoimmune and autoimmune-related applications including vitiligo, alopecia areata, and type 1 diabetes (T1D). Its subsidiaries include Forte Subsidiary, Inc. and Forte Biosciences Australia Proprietary Limited.
Forte Biosciences Incの企業情報
企業コードFBRX
会社名Forte Biosciences Inc
上場日Apr 13, 2017
最高経営責任者「CEO」Wagner (Paul A)
従業員数14
証券種類Ordinary Share
決算期末Apr 13
本社所在地3060 Pegasus Park Drive
都市DALLAS
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号75247
電話番号13106186994
ウェブサイトhttps://www.fortebiorx.com/home/default.aspx
企業コードFBRX
上場日Apr 13, 2017
最高経営責任者「CEO」Wagner (Paul A)
Forte Biosciences Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
83.18K
+1086.00%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.60K
+221.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
Dr. Scott C. Brun, M.D.
Dr. Scott C. Brun, M.D.
Independent Director
Independent Director
--
--
Mr. Richard G. (Rich) Vincent, CPA
Mr. Richard G. (Rich) Vincent, CPA
Independent Director
Independent Director
--
--
Mr. Shiv Kapoor
Mr. Shiv Kapoor
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Paul A. Wagner, Ph.D.
Dr. Paul A. Wagner, Ph.D.
Chairman of the Board, President, Chief Executive Officer
Chairman of the Board, President, Chief Executive Officer
83.18K
+1086.00%
Mr. Antony A. Riley
Mr. Antony A. Riley
Chief Financial Officer
Chief Financial Officer
41.60K
+221.00%
Mr. David W. (Dave) Gryska
Mr. David W. (Dave) Gryska
Independent Director
Independent Director
5.94K
--
Mr. Steven Kornfeld
Mr. Steven Kornfeld
Independent Director
Independent Director
3.96K
--
Dr. Stephen K. Doberstein, Ph.D.
Dr. Stephen K. Doberstein, Ph.D.
Independent Director
Independent Director
--
--
Dr. Barbara K. Finck, M.D.
Dr. Barbara K. Finck, M.D.
Director, Senior Medical Clinician
Director, Senior Medical Clinician
--
--
収益内訳
会社から関連データがまだ開示されていません。
会社から関連データがまだ開示されていません。
事業別
地域別
会社から関連データがまだ開示されていません。
株主
更新時刻: Thu, Jan 22
更新時刻: Thu, Jan 22
株主統計
種類
株主統計
株主統計
比率
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Affinity Asset Advisors LLC
6.49%
他の
46.64%
株主統計
株主統計
比率
Fred Alger Management, LLC
13.06%
Federated Hermes Global Investment Management Corp.
13.05%
Janus Henderson Investors
11.21%
OrbiMed Advisors, LLC
9.56%
Affinity Asset Advisors LLC
6.49%
他の
46.64%
種類
株主統計
比率
Investment Advisor/Hedge Fund
46.65%
Hedge Fund
32.83%
Private Equity
9.56%
Investment Advisor
7.50%
Corporation
2.86%
Individual Investor
1.11%
Research Firm
0.12%
機関投資家保有株
更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
74
10.85M
55.59%
--
2025Q3
75
10.85M
55.60%
+222.21K
2025Q2
78
10.20M
43.87%
+4.95M
2025Q1
72
5.29M
79.85%
+32.05K
2024Q4
73
5.16M
31.17%
+3.22M
2024Q3
65
789.31K
58.51%
-26.11K
2024Q2
72
815.46K
58.79%
-11.24K
2024Q1
101
826.69K
59.45%
-38.71K
2023Q4
113
819.35K
60.39%
+5.27K
2023Q3
130
814.23K
49.33%
+164.66K
詳細を見る
株主動向
会社名
保有株式数
比率
変動額
変動率
日付
Fred Alger Management, LLC
1.64M
13.06%
+17.38K
+1.07%
Sep 30, 2025
Federated Hermes Global Investment Management Corp.
1.64M
13.05%
+156.73K
+10.60%
Sep 30, 2025
Janus Henderson Investors
1.40M
11.21%
+8.99K
+0.64%
Sep 30, 2025
OrbiMed Advisors, LLC
1.20M
9.56%
--
--
Sep 30, 2025
Affinity Asset Advisors LLC
840.00K
6.71%
+840.00K
--
Dec 17, 2025
Tybourne Capital Management (HK) Limited
786.65K
6.28%
--
--
Sep 30, 2025
The Vanguard Group, Inc.
566.74K
4.52%
+79.82K
+16.39%
Sep 30, 2025
Cable Car Capital LLC
500.00K
3.99%
--
--
Sep 30, 2025
Sphera Funds Management Ltd.
474.31K
3.79%
-20.80K
-4.20%
Sep 30, 2025
詳細を見る
関連ETF
更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
Alger 35 ETF
1.35%
Texas Capital Texas Small Cap Equity Index ETF
0.06%
iShares Micro-Cap ETF
0.01%
Dimensional US Core Equity 1 ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
Fidelity Nasdaq Composite Index ETF
0%
Alger Mid Cap 40 ETF
0%
Avantis US Small Cap Equity ETF
0%
Alger 35 ETF
比率1.35%
Texas Capital Texas Small Cap Equity Index ETF
比率0.06%
iShares Micro-Cap ETF
比率0.01%
Dimensional US Core Equity 1 ETF
比率0%
iShares Core S&P Total U.S. Stock Market ETF
比率0%
Fidelity Nasdaq Composite Index ETF
比率0%
Alger Mid Cap 40 ETF
比率0%
Avantis US Small Cap Equity ETF
比率0%
配当金
過去5年間の配当金総支払額は
0.00
米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし
株式分割
日付
配当落ち日
種類
比率
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
日付
配当落ち日
種類
比率
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Aug 22, 2024
Merger
25→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
Jun 15, 2020
Merger
15→1
